Company Presentation - J.P. Morgan Healthcare ... - MorphoSys

More documents

Recommendations

Info

Safe Harbour This presentation includes forward-looking forward looking statements. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties including changes in business, economic competitive conditions conditions, regulatory reforms, reforms foreign exchange rate fluctuations and the availability of financing. These and other risks and uncertainties are detailed in the Company’s Annual Report.
MorphoSys p y at a Glance � An independent antibody company Company �� Martinsried/Germany Martinsried/Germany, with sites in UK & US Business Technology Pipeline Financials Corporate � Frankfurt Stock Exchange – TecDAX � Th Therapeutic ti antibodies tib di � Research & diagnostic antibodies (AbD Serotec) � Leading, proprietary HuCAL platform � New technology from Sloning acquisition � Over 70 therapeutic antibody programs � Strong alliances with pharma companies � Sustainable profitability funds proprietary R&D � 10-year, $1bn strategic alliance with Novartis �� CCash h bbalance l iin excess of f $170 $170m Technology Pipeline AbD Serotec © MorphoSys AG Page 3
Page 1: Company p yUpdate p 29th Annual J.P
Page 5 and 6: New Technology gy Enhances Power of
Page 7 and 8: - Higher g Probabilities of Success
Page 9 and 10: MOR103 A Novel Anti-Inflammatory An
Page 11 and 12: MOR208 A Novel Anti-Cancer Antibody
Page 13 and 14: MOR202 A Novel Antibody for Multipl
Page 15 and 16: Partnered Programs g Phase 1 Clinic
Page 17 and 18: Current Pipeline p Projected HuCAL
Page 19 and 20: Technology gy Offers Exciting g Gro
Page 21 and 22: Shareholder Structure and Key y Fin
Page 23 and 24: Forthcoming g Events MOR103 � Com

Company Presentation - J.P. Morgan Healthcare ... - MorphoSys

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?